About Event

Welcome to the 2nd mRNA Quality Control & Compliance Summit

Addressing key challenges in purification, potency, manufacturing consistency & LNP payloads and heterogeneity, this year’s summit will address some of your burning questions such as:

How to identify, evaluate, and mitigate potential quality risks associated with raw & starting materials to expedite mRNA product approval processes?
How to address complexities of analysing LNP payload, including mRNA encapsulation & distribution to ensure efficient mRNA delivery efficacy in line with guidelines?
How to develop robust statistical methodologies used for stability data trending & shelf-life assessment to develop more stable and effective mRNA medicines?

 

With world-class speakers from the likes of CureVac, Intellia Therapeutics, Zipcode Bio, Tessera Therapeutics, and many more, join this technical forum alongside 80+ global attendees for actionable insights to remain at the forefront of advances in mRNA quality control and ensure compliance whilst streamlining your pipelines towards cost-effective and superior quality mRNA medicines for patients in need.

The Brand-New 2024 Agenda Snapshots

3
4
5
6
7

Engage in bespoke discussions highlighting ongoing statistical methodologies being used to optimize targeted and effective delivery of
your mRNA vaccines with insights from Zipcode Bio, Alnylam & John
Hopkins University

Examining regulatory guidelines related to the control of raw materials in mRNA production, and considering the strategies for effective supply chain management to ensure a consistent and high-quality raw material supply towards safeguarding approval of your mRNA medicines with insights from Pfizer, Intellia Therapeutics & Sanofi

Navigate the intricacies of developing and producing mRNA therapeutics whilst maintaining accuracy,accessibility and compliance of the documentation, to ensure mRNA drug regulatory adherence, reproducibility & efficacy with the University of Massachusetts & CureVac

Explore the complexities of developing potent mRNA vaccines while adhering to regulatory standards. Discuss strategies with industry leaders to optimize product quality,design, and potency assessment for multivalent vaccines with insights from Seqirus & Abogen

Discover the latest advances in critical quality attribute testing and strategies for quality control documentation. Learn phased approaches for enhanced mRNA quality control and create a regulatory compliance roadmap with insights from Tessera Therapeutics &CureVac

This is your opportunity to remain up to date on the latest breakthroughs in quality control procedures from key stakeholders of the mRNA community